Skip to main content
Premium Trial:

Request an Annual Quote

Protein-biomarker Dx Firm Astute Medical Raises $26.5M


This story originally ran on May 10.

Protein-biomarker diagnostic firm Astute Medical today announced it has secured $26.5 million in Series B financing.

The money will be used to advance R&D aimed at identifying and validating protein biomarkers for diagnostic purposes and to develop and commercialize products based on the biomarkers, the San Diego firm said in a statement.

Venture capital firms Domain Associates and Delphi Ventures led this round of financing. Johnson & Johnson and De Novo Ventures also participated.

"With this financing, the resources are in place to conduct clinical studies that will move us closer to commercialization of promising diagnostic products currently in development," said Christopher Hibberd, CEO of the company. He declined further comment.

In its statement, the company said that the focus of its research is hospital- and community-acquired conditions that require rapid diagnosis and risk assessment. The areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis.

Hibberd and Paul McPherson, both formerly of Biosite, founded Astute in 2007. Two years, ago the company said it had raised $6.25 million in an initial financing round led by De Novo Ventures.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.